Pfizer Q2 2026: Revenue $15.0B, raises FY guidance midpoint by $500M, reports net loss on $4.3B impairments

PFIZER INC

2026-Q2 EPS reported $0.43 vs consensus $0.69 ▼ miss (-37.8%)

Q2 revenue $15.0B (+1% operational); launched/acquired products grew 18% operationally.
Reported net loss $248M ($0.04 LPS) from $4.3B impairments; adjusted EPS $0.77 flat YoY.
Raises FY2026 revenue guidance to $60.5-$62.5B (midpoint +$500M); reaffirms adjusted EPS $2.80-$3.00.
Announces additional $2.5B in productivity savings from 2027-2029; ongoing cost realignment program.
Pipeline: Lorbrena 7-yr PFS HR 0.19, Padcev MIBC approval, Litfulo vitiligo Phase 3 positive, sigvotatug vedotin miss.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.